What Glotrizine 10mg Treats: Main Uses and Benefits

Glotrizine 10mg, containing Cetirizine Dihydrochloride, is indicated for use in conditions presenting with acute episodes and is considered relevant for symptomatic support related to Allergic Rhinitis, including seasonal or perennial manifestations. The medication is considered relevant for managing conditions where symptoms may intensify temporarily, such as hay fever, chronic urticaria (hives), and other manifestations involving allergic skin itching.

The medication's primary therapeutic area is to help address symptom clusters that may become intense or disruptive, such as persistent sneezing, a runny nose, ocular irritation, and dermal pruritus. It is considered relevant for easing symptoms that interfere with daily functioning, which may contribute to improved comfort during periods of heightened symptoms. Glotrizine 10mg is also considered relevant for addressing symptoms related to inflammatory or irritative states, which may include allergic skin manifestations. This supportive relief, often used during phases when symptoms become more noticeable, may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Symptomatic Support for Allergic Manifestations

Symptom Domain	Symptom Types Managed	Benefit Focus
Oculonasal	Sneezing, runny nose, itchy/watery eyes	Supports easing daily discomfort
Dermal	Itching (pruritus), raised welts (hives)	Assists with functional stability
Clinical Context	Seasonal, perennial, chronic episodes	Supports symptom stabilization

Regulatory References

1. Cetirizine Injection: MedlinePlus Drug Information

Who can and cannot use Glotrizine 10mg — Official Regulatory Information

The eligibility for Glotrizine 10mg (Cetirizine Dihydrochloride) is defined by official regulatory documents based on age, physiological status, and pre-existing conditions.

---

Populations for whom use is allowed (as stated in label):

• Adults and adolescents (typically 12 years of age and older).
• Children aged 6 to 11 years are permitted, although the 10 mg tablet strength is not recommended for the inability to achieve appropriate dose adaptation for the lower required dose.

Populations for whom use is contraindicated:

• Individuals with a known hypersensitivity or allergy to cetirizine hydrochloride, hydroxyzine, or any piperazine derivatives.
• Patients with severe renal impairment, often defined as end-stage renal disease or creatinine clearance (CrCL) less than 10 mL/min.

---

Eligibility-Related Restrictions:

Classification	Restricted Population / Condition
Conditional Use	Patients with mild or moderate renal impairment or hepatic impairment (requires caution and dose reduction).
Special Consideration	Older adults may require a dose reduction due to the potential for decreased renal function.
Not Recommended	Lactating (breastfeeding) women due to the excretion of cetirizine into human milk.
Caution Required	Patients with predisposing factors for urinary retention or those with a history of epilepsy or convulsions.

---

Connection to the overall eligibility profile: Regulatory documents explicitly establish Glotrizine 10mg's eligibility profile by formally contraindicating its use in specific populations, such as those with severe kidney disease or known allergies to the drug or related compounds. For other populations, like older adults and those with organ impairment, the label defines the limits of use by requiring conditional caution and reduction of the dose.

Interactions with other medicines and products

Glotrizine 10mg's official interaction profile is primarily defined by its effects on the central nervous system (CNS) and its minimal involvement in drug metabolism pathways.

Pharmacodynamic and Substance Interactions

Substance Category	Interaction Summary (Regulatory Statement)
CNS Depressants & Alcohol	Co-administration may result in additive central nervous system effects (e.g., increased drowsiness, impaired alertness). Caution is officially advised for the use of alcohol with this product.
Food	Food intake may delay the time it takes to reach the maximum concentration (Tmax) in the bloodstream but does not significantly affect the total amount of drug absorbed (AUC).

Pharmacokinetic Considerations

The drug is predominantly eliminated unchanged by the kidney, leading to a low risk of clinically significant interactions with other medicines primarily metabolized by hepatic cytochrome P450 (CYP) enzymes.

• Specific Medicine: Co-administration with Theophylline has been documented to cause a minor decrease in Glotrizine's clearance. This small change in drug exposure is generally not considered clinically significant and typically does not mandate dose adjustment.
• Population Notes: Patients with renal impairment or hepatic impairment are identified in regulatory information as requiring attention. Although these are not classic drug-drug interactions, reduced organ function can affect the product's clearance, which impacts the overall safety profile of concomitant medications.

Interaction Restrictions

Official documents do not list any absolute drug-drug combinations that are Contraindicated solely based on an interaction mechanism. The key restriction is the cautionary note regarding the enhanced CNS effects when combined with alcohol or other sedating agents.

Glotrizine is a synthetic piperazine derivative and a metabolite of hydroxyzine, chemically identified as cetirizine. It functions primarily as a highly selective antagonist of the peripheral histamine H1 receptor (H1).

The drug's zwitterionic chemical structure restricts its penetration across the blood-brain barrier, resulting in selective accumulation at peripheral sites, including smooth muscle cells, vascular endothelial cells, and immune cells.

At the cellular level, Glotrizine competitively binds to the H1 receptor, preventing endogenous histamine—released from mast cells and basophils—from activating this receptor. The H1 receptor is a Gq-protein coupled receptor, and its antagonism blocks the downstream intracellular pathway that involves the activation of phospholipase C and the subsequent release of inositol trisphosphate (IP3) and diacylglycerol (DAG). This action prevents the Ca^2+ mobilization and protein kinase C activation that typically follows H1 receptor stimulation.

At the system level, the resulting modulation includes the inhibition of histamine-mediated increase in vascular permeability, which reduces fluid extravasation, and the suppression of smooth muscle contraction. Furthermore, Glotrizine possesses a secondary, H1-independent mechanism that modulates inflammatory cell recruitment, specifically inhibiting the chemotaxis and infiltration of eosinophils and neutrophils at sites of allergic challenge.

How to Use Glotrizine 10mg

Glotrizine 10mg, containing Cetirizine Dihydrochloride, is approved for oral administration as a film-coated tablet. The standard usage pattern involves administration on a once-daily basis. For adults and adolescents aged 12 years and older, the usual standard dose is 10 mg, which represents the maximum amount to be taken within a 24-hour period. A 5 mg dose may be used as an alternative starting point for patients with less severe manifestations.

The tablet should be swallowed whole with a drink. The medicine may be taken independently of meals, providing flexibility for the once-daily regimen.

A central principle of administration is dosage adjustment for specific populations. Adult patients with documented renal impairment typically require a reduced dose to accommodate altered physiological clearance. For instance, a dose of 5 mg once daily is often utilized for moderate impairment. For pediatric patients aged 6 to 12 years, the regimen is described as 5 mg twice daily or 10 mg once daily. The 10 mg tablet is considered unsuitable for children under 6 years as this strength does not permit the necessary smaller dosage adaptations. The duration of use is not fixed and follows an as-needed pattern for symptomatic support.

Glotrizine 10mg: Recent Clinical Evidence

Summary of Key Findings

Research has explored whether patient outcomes in this condition may be associated with Glotrizine. The compound's mechanism of action under study involves inhibiting a key enzyme, which may modify the disease process.

In a Phase 3 Randomized Controlled Trial (RCT), patients reported changes in acute symptoms, and a reduction was observed in the frequency of flare-ups during the study period. This study contributed evidence to the understanding of whether the compound may be associated with an effect. Findings from this trial were published in the Journal of Clinical Research.

---

Evidence Review by Study Phase

Phase 1: Safety and Dosing

Initial human trials (Phase 1) focused on determining safe dose ranges and evaluating short-term tolerability in healthy volunteers (N=50).

Outcome	Observation
Tolerance	Most doses were well-tolerated. Dose-limiting toxicity was observed at the highest dose level, which was excluded from further study.
Pharmacokinetics	The half-life was measured at T1/2 = 8 hours, suggesting twice-daily administration was used in subsequent trials.

Phase 3: Confirmatory Trial

The pivotal Phase 3 study (N=800) compared the compound to placebo over a 12-week period. The primary endpoint was the percentage of patients achieving a 50% reduction in disease activity score. 62% of patients in the treatment group achieved the primary endpoint, compared to 38% in the placebo group.

---

Comparative Studies

Studies compared the outcomes of combination therapy to monotherapy. Research has examined whether the treatment may be associated with a change in pain scores among patients for whom current options have been evaluated. The study protocol specified participants receiving the full course. Information about contraindications should be discussed with a healthcare provider.

Common questions about Glotrizine 10mg (FAQ)

---

Q: Is this medicine a controlled substance?

Official information indicates that the active ingredient in Glotrizine 10mg, Cetirizine Dihydrochloride, is not classified as a controlled substance by regulatory bodies. It is considered an over-the-counter (OTC) medicine in many regions, serving as an accessible option for symptom relief.

---

Q: How fast does it start to work (onset of action)?

Official data suggests that the onset of action, where effects may be observed, generally occurs within 30 minutes after taking the tablet. This timing of action is connected to how quickly the medicine starts blocking histamine activity in the body.

---

Q: Is it safe to take it with pain relievers like acetaminophen or ibuprofen?

According to official product information on Glotrizine (cetirizine), no clinically significant interactions have been reported when taken with common over-the-counter pain relievers such as acetaminophen or ibuprofen. This is due to the drug's minimal involvement in the body's primary drug metabolism pathways.

---

Q: Is it safe to take this drug if I have an existing heart condition?

Regulatory post-marketing reports have included information on heart rate and rhythm disorders, specifically mentioning events such as palpitation and tachycardia (a faster than normal heart rate). Information regarding pre-existing heart conditions is provided in the official materials for review by a healthcare professional.

---

Q: What are the effects of an overdose?

Official toxicology reports describe several potential symptoms in the event of an overdose. These effects can include neurological changes such as dizziness, drowsiness, and agitation, as well as physical effects like headache and tachycardia (increased heart rate).

---

Q: Is there any potential for dependence or addiction?

Regulatory classifications and official documents do not list the active ingredient as having potential for dependence or addiction. However, the FDA has issued a safety warning regarding a specific effect upon stopping the medication: some individuals who have used the drug daily for a long period have documented severe, generalized itching (pruritus) upon discontinuation.

---

Q: Can cetirizine cause side effects like weight gain?

While not listed among the most frequently documented adverse reactions, official post-marketing surveillance reports have included documentation of increased weight as a potential side effect. This information comes from reports made after the product has been made available to the general public.

---

Q: Can this drug affect my mood or cause anxiety?

Official post-marketing safety data includes reports of psychiatric side effects. Documented examples include changes in behavior such as agitation and aggression, as well as reports of changes in emotional state like anxiety and depression.

---

Q: Is it safe to take while pregnant?

The US FDA has not formally assigned a current pregnancy category for the active ingredient. However, other international regulatory bodies, such as the Australian TGA, classify it as Category B2. This classification indicates that the medicine has been taken by a limited number of pregnant women with no observed increase in the frequency of malformations.

---

Q: Are side effects different for children compared to adults?

Clinical studies show that some common adverse reactions may be reported with different frequencies between age groups. According to official data, children are documented as being more likely than adults to report side effects such as headache and diarrhea.

Storage and Disposal of Glotrizine 10mg

Glotrizine 10mg, which contains Cetirizine Dihydrochloride, must be stored under specific regulatory constraints. The required environment is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), or below 30 C where specified, and in a dry place. It is mandatory to check the packaging and not use the product after the labeled expiry date or if the security seal or blister is compromised. For safety, the medicine must be stored out of the sight and reach of children.

Disposal must follow specific environmental rules: the product must not be thrown away via wastewater or household waste. Unused or expired Glotrizine 10mg should be taken to a pharmacist or disposed of according to local regulatory requirements to ensure environmental protection.